Mechanism of action
Prussian blue is an insoluble crystalline compound with a lattice structure that selectively binds cesium and thallium cations through adsorption and mechanical trapping. After oral administration, it remains in the gastrointestinal lumen where it traps these metals and prevents their absorption.
The primary mechanism involves interruption of enterohepatic and enteroenteric recirculation. Cesium and thallium are normally secreted in bile and reabsorbed from the intestine. Prussian blue binds these metals in the intestinal lumen through adsorption into its crystalline lattice, forming a stable complex that is eliminated in feces. This accelerates clearance by up to 50% and reduces the biological half-life.
The crystal structure creates small channels and binding sites that preferentially accommodate cesium (ionic radius 1.67 Å) and thallium (ionic radius 1.50 Å) while excluding most other cations. The metals are mechanically trapped within the lattice structure. The resulting complexes are not absorbed and pass through the GI tract unchanged. During this process, Prussian blue can bind potassium from the gastrointestinal contents, which may lead to potassium depletion with prolonged use.
Prussian blue does not chelate metals already deposited in tissues. Its effect is limited to the gastrointestinal tract, making early administration critical for maximum efficacy.
- Prussian blue binds cesium-137 and thallium in the gut by adsorption and mechanical trapping, preventing absorption and interrupting enterohepatic recirculation.
- It is the only FDA-approved treatment for internal radioactive cesium contamination (e.g., nuclear accidents).
- Prussian blue is NOT absorbed systemically; it acts only in the GI lumen and is excreted unchanged in feces.
- Most common side effect is constipation; blue stool is universal and expected.
- Monitor serum potassium during prolonged therapy as Prussian blue can bind potassium from the GI tract causing hypokalemia.
- Most effective when started early but remains beneficial for weeks due to prolonged enterohepatic recirculation of cesium/thallium.
- Classic thallium poisoning triad: alopecia, painful neuropathy, GI symptoms; Prussian blue accelerates elimination.
- No absolute contraindications for life-threatening radioactive contamination; benefits outweigh risks even in pregnancy.
Indications
Prussian blue is indicated for:
- Radioactive cesium contamination: Internal contamination with cesium-137 (Cs-137) from nuclear accidents or radiological dispersal devices. It is the only FDA-approved treatment for cesium contamination.
- Radioactive thallium contamination: Internal contamination with radioactive thallium isotopes (Tl-201).
- Non-radioactive thallium poisoning: Acute or chronic thallium poisoning from occupational exposure, contaminated food, or intentional poisoning.
Prussian blue is most effective when started as early as possible after contamination. It continues to be beneficial even with delayed treatment because cesium and thallium undergo prolonged enterohepatic recirculation. Treatment typically continues until contamination levels fall below safety thresholds, which may require weeks to months depending on the body burden.
The drug is approved for both adults and children. Pediatric dosing follows body weight guidelines. Pregnant and breastfeeding women with significant contamination should receive treatment as the benefits outweigh theoretical risks.
Pharmacokinetics
Absorption: Prussian blue is not absorbed from the gastrointestinal tract. It acts locally within the intestinal lumen and is eliminated unchanged in feces.
Distribution: No systemic distribution occurs. The drug remains within the GI tract throughout its transit.
Metabolism: Prussian blue is not metabolized. It remains chemically stable in the acidic and alkaline environments of the stomach and intestines.
Excretion: Complete fecal elimination occurs, typically within 24-48 hours of administration. The cesium-Prussian blue and thallium-Prussian blue complexes are excreted intact.
Onset and duration: Metal binding begins immediately upon contact in the stomach and continues throughout intestinal transit. Maximum efficacy requires continuous dosing to maintain adequate concentrations in the gut lumen. The enterohepatic circulation of cesium and thallium means that even metals absorbed days earlier will eventually be secreted into bile and can be trapped by Prussian blue during subsequent passes through the intestine.
No dose adjustment is needed for renal or hepatic impairment since systemic absorption does not occur.
Adverse effects
Prussian blue is generally well tolerated because it is not systemically absorbed. Most adverse effects are gastrointestinal and cosmetic.
Common adverse effects
- Constipation: The most frequent side effect, occurring in approximately 10-25% of patients. Increased fluid intake and stool softeners may be needed.
- Blue discoloration of stool: Universal effect due to the blue color of the compound. Patients should be counseled that blue feces are expected and harmless.
- Gastrointestinal upset: Mild nausea, bloating, or abdominal discomfort may occur.
Serious adverse effects
- Severe constipation or bowel obstruction: Rare but possible with high doses or inadequate fluid intake, particularly in elderly patients or those with preexisting GI motility disorders.
- Hypokalemia: Prolonged high-dose therapy may lead to potassium depletion because Prussian blue can bind potassium from the gastrointestinal tract. Electrolyte monitoring is recommended during extended treatment.
- Blue discoloration of mouth and teeth: Temporary staining may occur, especially in children.
Monitoring
During treatment, monitor serum potassium levels weekly, especially with high doses or prolonged therapy. Whole-body counting or urine/fecal radioactivity measurements guide treatment duration for radioactive contamination.
Contraindications and warnings
Absolute contraindications: There are no absolute contraindications when treating life-threatening radioactive contamination. The benefits of reducing radiation exposure outweigh potential risks.
Relative contraindications:
- Gastrointestinal obstruction or severe motility disorders: Prussian blue could worsen obstruction or cause fecal impaction. Use with caution and ensure adequate hydration and bowel monitoring.
- Severe constipation: Preexisting severe constipation should be managed before initiating therapy.
Warnings and precautions
Electrolyte disturbances: Monitor potassium levels during prolonged treatment. Consider potassium supplementation if levels decline.
Pregnancy and lactation: Prussian blue is not absorbed systemically, so direct fetal or infant exposure through maternal blood is unlikely. However, data are limited. For significant radioactive contamination, treatment is recommended as radiation exposure poses greater risk to the fetus than the drug itself. Breastfeeding may continue during treatment as the drug does not enter breast milk, though radioactive contaminants may be excreted in milk and should be monitored.
Pediatric use: Approved and safe for children. Dosing is weight-based. Parents should be counseled about blue stool to avoid unnecessary concern.
Handling precautions: Stool from patients treated for radioactive contamination will contain radioactive material and should be handled appropriately per radiation safety protocols.
Interference with absorption: Prussian blue does not significantly impair absorption of nutrients or most medications, but spacing of other oral drugs by 2 hours may optimize their absorption.
Drug interactions
Prussian blue has minimal drug interactions because it is not absorbed and acts only in the gastrointestinal lumen.
Potential interactions:
- Oral medications: Prussian blue may physically bind or reduce absorption of certain oral drugs, particularly those that are cationic or have large surface areas. Administering other medications at least 2 hours before or after Prussian blue minimizes this risk.
- Electrolyte supplements: Potassium and other cationic supplements may compete with cesium or thallium for binding sites. However, the large binding capacity of Prussian blue generally accommodates both therapeutic ions and target toxins.
- Tetracyclines: Theoretical interaction exists since tetracyclines can chelate metals, but clinical significance is minimal. Separate administration times are prudent.
No significant interactions with cytochrome P450 enzymes, plasma protein binding, or renal excretion occur because Prussian blue does not enter systemic circulation.
Patients on multiple medications should have drug administration times staggered to avoid potential binding in the gut lumen. In emergency contamination scenarios, the priority is initiating Prussian blue treatment even if optimal timing with other drugs cannot be achieved.
Clinical pearls
- Early administration is critical: Prussian blue is most effective when started immediately after contamination, but remains beneficial for weeks because cesium and thallium continue to recirculate enterically.
- Duration of treatment: Continue until whole-body or urine counts indicate contamination is below safety limits. This may require weeks to months of daily dosing.
- Blue stool is expected: Counsel patients that bright blue feces are normal and indicate the drug is working. Failure to warn patients may cause unnecessary anxiety.
- Hydration and bowel management: Encourage high fluid intake and use stool softeners prophylactically to prevent constipation, especially in elderly patients.
- Combination with other measures: Prussian blue should be part of comprehensive decontamination including external decontamination, gastric lavage if ingestion was recent, and supportive care.
- Thallium poisoning symptoms: Classic findings include alopecia (hair loss starting 2-3 weeks after exposure), painful peripheral neuropathy, and Mees lines on nails. Prussian blue accelerates clearance but does not reverse established tissue damage.
- Not a chelator for other metals: Prussian blue is specific for cesium and thallium. It does not treat lead, mercury, arsenic, or iron poisoning. Do not confuse with deferoxamine or other chelators.
- Radiation safety: Feces and potentially vomit from patients with radioactive contamination contain radioactive material. Use appropriate precautions and disposal methods.
- Exam tip: Prussian blue is the first-line treatment for cesium-137 contamination (nuclear accidents). For thallium, it competes with hemodialysis but is preferred for sustained elimination.
Practice questions
1. A 34-year-old nuclear power plant worker presents to the emergency department 4 hours after a radiation exposure incident. Whole-body counting confirms internal contamination with cesium-137. He is alert and has no acute symptoms. Which of the following best describes the mechanism by which the most appropriate pharmacologic treatment reduces his radiation exposure?
2. A 28-year-old woman is treated with Prussian blue for 3 weeks following confirmed thallium poisoning. She reports that her stools have been bright blue throughout treatment. Laboratory studies show: Potassium 3.0 mEq/L (normal 3.5-5.0), Sodium 138 mEq/L (normal 136-145), Chloride 102 mEq/L (normal 98-106). Which of the following is the most appropriate next step?
3. A 45-year-old man develops alopecia, severe burning pain in his feet, and abdominal cramping 3 weeks after an unclear toxic exposure at his workplace. He works in a facility that manufactures optical lenses. Laboratory testing confirms the diagnosis, and appropriate chelation therapy is initiated. Which of the following characteristics applies to the drug used in this patient's treatment?
Frequently asked questions
How does Prussian blue work?
Prussian blue works by binding cesium and thallium ions in the gastrointestinal tract through adsorption and mechanical trapping within its crystalline lattice structure. It remains in the gut lumen without being absorbed and traps these metals, preventing their absorption from food or interrupting their enterohepatic recirculation. The metal-Prussian blue complexes are then eliminated in feces, reducing the body burden and biological half-life of these toxins by up to 50%.
What are the side effects of Prussian blue?
The most common side effects of Prussian blue are constipation (10-25% of patients) and blue discoloration of stool, which occurs in all patients and is harmless. Mild gastrointestinal upset including nausea or bloating may occur. Serious but rare effects include severe constipation or bowel obstruction, especially with inadequate hydration. Prolonged high-dose therapy can cause hypokalemia requiring electrolyte monitoring. Temporary blue staining of the mouth and teeth may occur in children.
Is Prussian blue absorbed into the bloodstream?
No, Prussian blue is not absorbed into the bloodstream. It is an insoluble compound that remains entirely within the gastrointestinal lumen throughout its transit. It acts locally by binding cesium and thallium in the gut and is eliminated unchanged in feces within 24-48 hours. Because it is not systemically absorbed, it does not distribute to tissues, undergo metabolism, or require dose adjustment for kidney or liver impairment.
What is Prussian blue used to treat?
Prussian blue is used to treat internal contamination with radioactive cesium-137 (from nuclear accidents or radiological incidents), radioactive thallium isotopes, and non-radioactive thallium poisoning. It is the only FDA-approved treatment for cesium contamination. Thallium poisoning can result from occupational exposure, contaminated food, or intentional poisoning. The drug enhances elimination of these metals by trapping them in the gut and preventing their reabsorption from bile secretions.
How long does Prussian blue treatment last?
Prussian blue treatment continues until internal contamination falls below safety thresholds, which is monitored by whole-body counting or urine/fecal radioactivity measurements. Treatment duration depends on the initial body burden and typically ranges from several weeks to months. Daily dosing is required throughout this period to maintain adequate drug levels in the gut and continuously trap metals as they undergo enterohepatic recirculation. Early initiation improves outcomes, but the drug remains effective even with delayed treatment.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: V03AB31
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.